Mesa Laboratories, Inc. ( MLAB ) NASDAQ Global Select

Cena: 72.71 ( 8.67% )

Aktualizacja 08-22 21:58
NASDAQ Global Select
Branża: Hardware, Equipment & Parts
Finanse
Rachunek zysków i strat
Bilans
Przepływy pieniężne
Prognozy
Statystyki
Dywidendy
Rekomendacje
Modele wyceny
Wskaźniki
Analiza techniczna

Notowania:

Opis firmy:

Mesa Laboratories, Inc. opracowuje, produkuje i sprzedaje narzędzia i usługi kontroli jakości życia w Stanach Zjednoczonych, Europie, Azji i Pacyfiku i na arenie międzynarodowej. Segment kontroli sterylizacji i dezynfekcji firmy produkuje i sprzedaje wskaźniki biologiczne, czyszczące i chemiczne, które są wykorzystywane do oceny skuteczności procesów sterylizacji i dezynfekcji w branży szpitala, dentystycznej, medycznej i przemysłu farmaceutycznego. Ten segment zapewnia również usługi testowe i laboratoryjne przede wszystkim dla branży dentystycznej. Jego segment rozwoju biofarmaceutycznego rozwija, produkuje i sprzedaje zautomatyzowane systemy do analizy białek (testy immunologiczne) i roztworów syntezy peptydów. Rozwiązania tego segmentu obejmują analizę białek obejmującą sprzęt analizy, płyty CD, zestawy i bufory; oraz syntezy peptydowe, które umożliwiają automatyzację chemicznie syntetyzowanych peptydów, które są stosowane w tworzeniu terapii peptydowych, biomateriałów, kosmetyków i badań ogólnych. Rozwiązania kalibracyjne Spółki projektuje produkty, produkuje i sprzedaje produkty kontroli jakości i kalibracji jakości w celu pomiaru lub kalibrującej temperatury, ciśnienia, pH, wilgotności i innych takich parametrów stosowanych do celów zdrowia i bezpieczeństwa w szpitalu, produkcji urządzeń medycznych, produkcji farmaceutycznej oraz różnych środowiskach laboratoryjnych i opieki zdrowotnej. Produkty tego segmentu obejmują ciągłe systemy monitorowania, mierniki dializowania i materiały eksploatacyjne, rejestrator danych, sprzęt do kalibracji przepływu gazu i sprzęt do próbkowania powietrza oraz systemy testowania momentu obrotowego. Jego segment genomiki klinicznej rozwija się, produkuje i sprzedaje narzędzia analizy genetycznej, które obejmują system masarray i materiały ekspresowe, w tym układy, panele i roztwory odczynników chemicznych stosowane przez laboratoria kliniczne do przeprowadzenia testów klinicznych genomowych w kilku obszarach terapeutycznych, takich jak badania noworodka, farmakogenetyka i onkologia. Firma została zarejestrowana w 1982 roku i ma siedzibę w Lakewood w Kolorado.

Informacje o spółce:
Sektor: Technologia
Branża: Hardware, Equipment & Parts
Zatrudnienie: 736
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 95.9811
Ilość akcji: Brak danych
Debiut giełdowy: 1984-02-29
WWW: https://www.mesalabs.com
CEO: Mr. Gary M. Owens
Adres: 12100 West Sixth Avenue
Siedziba: 80228 Lakewood
ISIN: US59064R1095
Wskaźniki finansowe
Kapitalizacja (USD) 400 010 429
Aktywa: 454 098 000
Cena: 72.71
Wskaźnik Altman Z-Score: -0.6
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 1
P/E: -559.3
Ilość akcji w obrocie: 96%
Średni wolumen: 155 262
Ilość akcji 5 501 450
Wskaźniki finansowe
Przychody TTM 228 380 000
Zobowiązania: 292 647 000
Przedział 52 tyg.: 55.45 - 155.12
Piotroski F-Score: 5
Umiarkowany (średnia jakość finansowa)
EPS: -0.1
P/E branży: 24.4
Beta: 0.865
Raport okresowy: 2025-11-06
WWW: https://www.mesalabs.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. John V. Sakys Vice President, Chief Financial Officer & Chief Accounting Officer 582 288 1969
Mr. Brian David Archbold Senior Vice President of Continuous Improvement 513 642 1976
Mr. Gary M. Owens Chief Executive Officer, President & Director 1 100 714 1968
Lista ETF z ekspozycją na akcje Mesa Laboratories, Inc.
Symbol ETF Ilość akcji Wartość
IJR 334 103 25 552 160
IWM 127 852 9 778 134
SPSM 46 890 3 704 042
IWO 46 274 3 539 065
IJT 32 693 2 500 324
VTWO 26 401 2 487 502
SCHA 25 581 1 994 846
VIOO 18 025 1 698 315
SLYG 18 017 1 419 967
IJS 17 539 1 341 412
VHT 17 064 1 607 770
RBOT.MI 15 011 1 004 302
2B76.DE 15 011 1 004 302
RBOT.L 15 011 1 148 037
RBOD.L 15 011 1 148 037
RBTX.L 15 011 868 926
2B7F.DE 15 011 1 004 302
DFAS 13 835 1 058 100
DES 11 736 897 569
DFAC 11 259 861 088
FSMD 10 985 848 701
SLYV 10 803 862 315
AVSC 10 539 830 473
IUS3.DE 8 198 548 509
IDP6.L 8 198 627 011
ISP6.L 8 198 474 572
ZPRR.DE 8 005 552 386
R2US.L 8 005 630 794
R2SC.L 8 005 478 009
ITOT 6 676 510 545
GSSC 5 896 535 297
IUSN.DE 5 849 391 339
WSML.L 5 849 447 347
WLDS.L 5 849 338 588
PSCH 5 210 410 548
PRFZ 4 949 389 981
EES 4 710 360 220
VTWG 4 616 434 919
CT2B.AS 4 349 332 614
CITY.AS 4 349 332 614
AYEU.DE 4 349 290 971
CT2B.L 4 349 251 749
CISB.SW 4 349 332 614
VIOG 4 336 408 537
VFMO 3 937 370 944
VIOV 3 646 343 526
XRS2.DE 3 610 241 794
XRSU.L 3 610 276 115
XRSG.L 3 610 20 923 733
DFAT 3 427 262 096
SCHB 3 259 255 842
PSC 2 987 228 445
SMLF 2 946 225 289
SIXS 2 839 0
RSSL 2 606 199 306
RWJ 2 448 192 902
VFMF 2 380 224 243
FHLC 2 353 181 792
SIXL 2 223 0
SMLV 2 190 174 480
IJR.AX 1 917 233 852
IWV 1 408 107 719
CAFG 1 400 107 072
DFAU 1 004 76 785
TILT 924 70 667
XSU.TO 892 97 117
QVMS 850 66 980
ISCV 661 50 589
OMFS 651 51 298
VMO.TO 626 80 480
ISCG 611 46 728
SPTM 570 44 967
SXRG.DE 527 35 225
CUSS.L 527 40 266
CUS1.L 527 30 477
CSUSS.MI 527 35 225
UWM 525 40 152
DFUV 459 35 104
URTY 436 33 345
XJR 426 33 568
VTHR 397 37 405
DFSU 365 27 915
DCOR 334 25 544
USSC.L 298 20 455
ZPRV.DE 298 17 912
BUYO 276 21 108
DTEC.L 250 14 704
DRUP.DE 250 16 996
UNIC.L 250 19 404
ISCB 246 18 833
XUU.TO 224 24 400
DXUV 199 15 219
XSMC.TO 191 20 825
XSMH.TO 177 19 263
SPGM 100 7 902
SAA 100 7 648
XGRO.TO 82 8 881
VLU 50 3 960
ESIX 43 3 407
XBAL.TO 38 4 088
XUH.TO 33 2 608
HDG 6 458
XCNS.TO 3 320
XTR.TO 1 105
SC0K.DE 0 33 062
USML.L 0 70 270
PZW.TO 0 1 820
USFM.L 0 0
RTYS.L 0 37 733
USUE.DE 0 0
Wiadomości dla Mesa Laboratories, Inc.
Tytuł Treść Źródło Aktualizacja Link
MESA LABS DECLARES QUARTERLY DIVIDEND LAKEWOOD, Colo., April 07, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 16, 2025, to shareholders of record at the close of business on May 30, 2025. globenewswire.com 2025-04-07 19:00:00 Czytaj oryginał (ang.)
What Makes Mesa Labs (MLAB) a New Strong Buy Stock Mesa Labs (MLAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). zacks.com 2025-03-26 15:00:31 Czytaj oryginał (ang.)
Why Mesa Labs (MLAB) Might be Well Poised for a Surge Mesa Labs (MLAB) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions. zacks.com 2025-02-11 15:21:09 Czytaj oryginał (ang.)
Mesa Labs (MLAB) Q3 Earnings and Revenues Beat Estimates Mesa Labs (MLAB) came out with quarterly earnings of $2.67 per share, beating the Zacks Consensus Estimate of $2.45 per share. This compares to earnings of $2.02 per share a year ago. zacks.com 2025-02-04 12:15:34 Czytaj oryginał (ang.)
Mesa Labs Announces Third Quarter Results LAKEWOOD, Colo., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its third fiscal quarter (“3Q25”) ended December 31, 2024 (amounts in thousands). globenewswire.com 2025-02-04 10:00:00 Czytaj oryginał (ang.)
Mesa Laboratories, Inc. to Announce Third Quarter Results on February 4, 2025 LAKEWOOD, Colo., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the third quarter of fiscal year 2025 at approximately 8:00 A.M. Eastern time on Tuesday, February 4, 2025. globenewswire.com 2025-01-17 15:15:00 Czytaj oryginał (ang.)
MESA LABS DECLARES QUARTERLY DIVIDEND LAKEWOOD, Colo., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 17, 2025, to shareholders of record at the close of business on February 28, 2025. globenewswire.com 2025-01-06 17:00:00 Czytaj oryginał (ang.)
Mesa Labs (MLAB) Lags Q2 Earnings and Revenue Estimates Mesa Labs (MLAB) came out with quarterly earnings of $2.45 per share, missing the Zacks Consensus Estimate of $2.48 per share. This compares to earnings of $1.91 per share a year ago. zacks.com 2024-11-07 12:20:20 Czytaj oryginał (ang.)
Mesa Labs Announces Second Quarter Results LAKEWOOD, Colo., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its second fiscal quarter (“2Q25”) ended September 30, 2024 (amounts in thousands). globenewswire.com 2024-11-07 10:00:00 Czytaj oryginał (ang.)
MESA LABS DECLARES QUARTERLY DIVIDEND LAKEWOOD, Colo., Oct. 02, 2024 (GLOBE NEWSWIRE) --  Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on December 16, 2024, to shareholders of record at the close of business on November 29, 2024. globenewswire.com 2024-10-02 18:00:00 Czytaj oryginał (ang.)
Surging Earnings Estimates Signal Upside for Mesa Labs (MLAB) Stock Mesa Labs (MLAB) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions. zacks.com 2024-08-26 17:20:21 Czytaj oryginał (ang.)
Mesa Labs (MLAB) Moves to Strong Buy: Rationale Behind the Upgrade Mesa Labs (MLAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). zacks.com 2024-08-26 17:01:14 Czytaj oryginał (ang.)
New Strong Buy Stocks for August 26th QFIN, GHM, CRNC, SUPV and MLAB have been added to the Zacks Rank #1 (Strong Buy) List on August 26, 2024. zacks.com 2024-08-26 11:25:29 Czytaj oryginał (ang.)
Mesa Labs Announces First Quarter Results LAKEWOOD, Colo., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its first fiscal quarter (“1Q25”) ended June 30, 2024 (amounts in thousands). globenewswire.com 2024-08-05 12:00:00 Czytaj oryginał (ang.)
MESA LABS DECLARES QUARTERLY DIVIDEND Lakewood, Colo, July 08, 2024 (GLOBE NEWSWIRE) --  Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 16, 2024, to shareholders of record at the close of business on August 30, 2024. globenewswire.com 2024-07-08 18:00:00 Czytaj oryginał (ang.)
Mesa Labs Announces Fourth Quarter and Full Fiscal Year 2024 Results LAKEWOOD, Colo., June 05, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its fourth fiscal quarter (“4Q24”) and fiscal year (“FY24”) ended March 31, 2024 (amounts in thousands). globenewswire.com 2024-06-05 10:00:00 Czytaj oryginał (ang.)
Mesa Laboratories, Inc. Revises Earnings Announcement date for Unaudited Fourth Quarter and Full Fiscal Year 2024 Results LAKEWOOD, Colo., May 31, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (“Mesa”) (NASDAQ:MLAB) will not issue its 2024 financial results for the fourth quarter and the fiscal year ending March 31, 2024 today as previously communicated. The earnings announcement has been delayed as we work to finalize our year end audit which is focused on finalizing the calculations and technical accounting for previously-announced impairments of long-lived assets and goodwill related to our Clinical Genomics and Biopharmaceutical Development divisions and the purchase accounting associated with the acquisition of GKE. globenewswire.com 2024-05-31 10:00:00 Czytaj oryginał (ang.)
Mesa Laboratories, Inc. Revises Earnings Announcement date for Unaudited Fourth Quarter and Full Fiscal Year 2024 Results to May 31, 2024 LAKEWOOD, Colo., May 22, 2024 (GLOBE NEWSWIRE) --  Mesa Laboratories, Inc. (“Mesa”) (NASDAQ:MLAB) will issue a press release with financial results for the fourth quarter and the fiscal year ending March 31, 2024 at approximately 8:00 A.M. Eastern time on Friday, May 31, 2024. Mesa's Form 10-K will be filed the same day. The earnings announcement has been delayed as we finalize the calculations and technical accounting for previously-announced impairments of long-lived assets and goodwill related to our Clinical Genomics and Biopharmaceutical Development divisions. globenewswire.com 2024-05-22 10:00:00 Czytaj oryginał (ang.)
MESA LABS ANNOUNCES AMENDMENT TO CREDIT FACILITY AND REPURCHASE OF SENIOR CONVERTIBLE NOTES Lakewood, Colo., April 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced the closing of its Amended and Restated Credit Agreement (the “Credit Agreement”), which provides up to $200 million of senior secured debt through a syndicate of banks led by JPMORGAN CHASE BANK, N.A. The Credit Agreement includes a $75 million senior secured term loan facility (the “Term Loan”) and a $125 million senior secured revolving credit facility (the “Revolver”), both of which mature in April 2029. The Credit Agreement includes a ten-year amortization schedule and no springing maturity relating to the Company's 1.375% Convertible Senior Notes due August 2025 (the “2025 Notes”). Both the Term Loan and the Revolver bear interest at a rate of SOFR plus an applicable margin ranging from 1.5% to 3.5%, depending on the Company's total Net Leverage Ratio. Proceeds from the Term Loan and Revolver will be used to pay down the Company's 2025 Notes and for normal operating expenditures. The Credit Agreement also allows funds to be used for permitted acquisitions. globenewswire.com 2024-04-08 12:00:00 Czytaj oryginał (ang.)
Best Value Stocks to Buy for April 8th SM and MLAB made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 8, 2023. zacks.com 2024-04-08 11:21:10 Czytaj oryginał (ang.)
MESA LABS DECLARES QUARTERLY DIVIDEND LAKEWOOD, Colo., April 04, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 14, 2024, to shareholders of record at the close of business on May 31, 2024. globenewswire.com 2024-04-04 22:24:00 Czytaj oryginał (ang.)
Mesa Laboratories, Inc. to Announce Unaudited Fourth Quarter and Full Fiscal Year 2024 Results on May 24, 2024 LAKEWOOD, Colo., April 01, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the fourth quarter and the fiscal year ending March 31, 2024 at approximately 8:00 A.M. Eastern time on Friday, May 24, 2024. globenewswire.com 2024-04-01 14:27:00 Czytaj oryginał (ang.)
Mesa Labs Releases Second Annual Responsible Business Program Brochure LAKEWOOD, Colo, March 15, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB, “Mesa” “we” “our” or the “Company”), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced the release of its second annual Environmental, Social and Governance ("ESG") Program Brochure. Rooted in Mesa's unwavering commitment to Protecting the Vulnerable®, this brochure highlights the Company's continued strides in environmental stewardship, social responsibility, and corporate governance. globenewswire.com 2024-03-15 09:00:00 Czytaj oryginał (ang.)
Mesa Labs (MLAB) Lags Q3 Earnings and Revenue Estimates Mesa Labs (MLAB) came out with quarterly earnings of $2.02 per share, missing the Zacks Consensus Estimate of $2.04 per share. This compares to earnings of $2.35 per share a year ago. zacks.com 2024-02-05 12:20:14 Czytaj oryginał (ang.)
Mesa Labs Announces Third Quarter Results LAKEWOOD, Colo., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its third fiscal quarter (“3Q24”) ended December 31, 2023. globenewswire.com 2024-02-05 10:00:00 Czytaj oryginał (ang.)
Mesa Laboratories Appoints Mark Capone to its Board of Directors LAKEWOOD, Colo., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa”, “we”, “us”, or “our”), a global leader in the design and manufacturing of life science tools and critical quality control solutions, today announced the appointment of Mark Capone to its Board of Directors (the “Board”), effective January 5, 2024. globenewswire.com 2024-01-08 10:00:00 Czytaj oryginał (ang.)
MESA LABS DECLARES QUARTERLY DIVIDEND LAKEWOOD, Colo. , Jan. 04, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that on January 2, 2024 its Board of Directors declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 15, 2024, to shareholders of record at the close of business on February 29, 2024. globenewswire.com 2024-01-04 17:00:00 Czytaj oryginał (ang.)